HLA-B27、中轴型脊柱关节炎与生存
基于1985年瑞士强直性脊柱炎患者及亲属筛查随访和英国生物样本库数据,强直性脊柱炎患者标化死亡率比为1.37(95%CI 1.11-1.62),HLA-B27阳性者及女性更显著;放射学阴性中轴型脊柱关节炎标化死亡率比为0.44(95%CI 0.23-0.77);一般人群中HLA-B27携带与死亡率无显著关联(HR 1,95%CI 0.97-1.1,p=0.349)。
要点
- 强直性脊柱炎患者标化死亡率比为1.37(95%CI 1.11-1.62),生存期较一般人群缩短。
- HLA-B27阳性强直性脊柱炎女性标化死亡率比为1.77(95%CI 1.09-2.70),男性为1.31(95%CI 1.02-1.59)。
- 放射学阴性中轴型脊柱关节炎标化死亡率比为0.44(95%CI 0.23-0.77),低于一般人群。
核心结论
- 强直性脊柱炎患者而非放射学阴性中轴型脊柱关节炎患者预期寿命显著缩短。
- HLA-B27阳性强直性脊柱炎女性死亡率增高尤为显著。
- 欧洲血统一般人群中HLA-B27携带不影响生存或血管性疾病死亡风险。
研究设计与样本
- 1985年对瑞士强直性脊柱炎患者协会363名成员及806名亲属进行临床和影像学筛查。
- 在377例有骨盆X线片和HLA-B27状态的中轴型脊柱关节炎患者中分析预期寿命,与匹配的瑞士人群数据比较。
- 利用英国生物样本库欧洲血统参与者(n=407480,n=30419例死亡)研究一般人群中HLA-B27状态与生存的关系。
主要发现
- 强直性脊柱炎患者标化死亡率比为1.37(95%CI 1.11-1.62),高于一般人群。
- HLA-B27阳性强直性脊柱炎标化死亡率比为1.38(95%CI 1.11-1.65),差异显著。
- HLA-B27阳性强直性脊柱炎女性标化死亡率比为1.77(95%CI 1.09-2.70),男性为1.31(95%CI 1.02-1.59)。
- 放射学阴性中轴型脊柱关节炎标化死亡率比为0.44(95%CI 0.23-0.77),显著低于一般人群。
- 英国生物样本库中HLA-B27携带与死亡率无显著关联(HR 1,95%CI 0.97-1.1,p=0.349,按性别调整),男性HR 1(95%CI 0.98-1.1,p=0.281),女性HR 0.96(95%CI 0.9-1,p=0.232),未见血管性疾病死亡率增加。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Ankylosing spondylitis (AS), and carriage of HLA-B27 gene in otherwise healthy individuals, are reportedly associated with increased mortality. We evaluated this hypothesis, using data from both a 35-year AS follow-up study and UK Biobank data. METHODS: In 1985, 363 members of the Swiss AS Patient Society and 806 relatives were screened clinically and then radiographically for AS/axial spondyloarthritis (axSpA). Life expectancy was analysed in 377 axSpA patients having available pelvic radiographs and HLA-B27 status, comparing with matched Swiss population data. Survival in relation to HLA-B27 status in the general population was studied in UK Biobank European-ancestry participants (n=407 480, n=30 419 deaths). RESULTS: AS patients have increased standardised mortality rate (SMR) compared with the general population (1.37, 95% CI 1.11 to 1.62). This increase was significant for HLA-B27-positive AS (SMR 1.38, 95% CI 1.11 to 1.65). Shortened life expectancy was observed among both HLA-B27-positive AS women (SMR 1.77, 95% CI 1.09 to 2.70) and men (SMR 1.31, 95% CI 1.02 to 1.59). Patients with non-radiographic axSpA (nr-axSpA) had significantly lower SMR: 0.44 (95% CI 0.23 to 0.77), compared with the general population. In the UK Biobank European-ancestry population cohort, HLA-B27 carriage was not significantly associated with any change in mortality (HR 1, 95% CI 0.97 to 1.1, p=0.349, adjusted by sex), in either males (HR 1, 95% CI 0.98 to 1.1, p=0.281) or females (HR 0.96, 95% CI 0.9 to 1, p=0.232), and no increase in vascular disease mortality was observed. DISCUSSION: AS patients, but not nr-axSpA patients, have a significantly shortened life expectancy. Increased mortality is particularly significant among women with HLA-B27-positive AS. HLA-B27 carriage in the European-ancestry general population does not influence survival, or the risk of death due to vascular disease.
引用
- Li Z, Khan MK, van der Linden SM, et al. HLA-B27, axial spondyloarthritis and survival. Ann Rheum Dis. 2023. PMID: 37679034. doi:10.1136/ard-2023-224434
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。